BioSpace

AbbVie bets up to $1.47B for Nxera’s discarded IBD program

AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.

By BioSpace

1 min read
AbbVie bets up to $1.47B for Nxera’s discarded IBD program
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights